CDKN2/p16 predicts survival in oligodendrogliomas: Comparison with astrocytomas

Journal of Neuro-Oncology

Volumn 41, Issue 3, 1999, Pages 205-211

  Miettinen, Helena ^a,b   Kononen, Juha ^c   Sallinen, Pauli ^b   Alho, Hannu ^f   Helen, Pauli ^b   Helin, Heikki ^b   Kalimo, Hannu ^d   Paljärvi, Leo ^e   Isola, Jorma ^c   Haapasalo, Hannu ^b  

^a UNIVERSITY OF TAMPERE MEDICAL SCHOOL   (Finland)

^b TAMPERE UNIVERSITY HOSPITAL   (Finland)

^c TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^d TURKU UNIVERSITY HOSPITAL   (Finland)

^e KUOPIO UNIVERSITY HOSPITAL   (Finland)

^f NONE

Author keywords

Astrocytoma; CDKN2 p16; Cyclins; Glioma; MTS1; Oligodendroglioma

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR; PROTEIN P16;

ADOLESCENT; ADULT; AGED; ARTICLE; ASTROCYTOMA; CANCER GRADING; CANCER SURVIVAL; CELL PROLIFERATION; CHILD; CONTROLLED STUDY; DISEASE COURSE; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MITOSIS INDEX; OLIGODENDROGLIOMA; PROGNOSIS; PROTEIN EXPRESSION; RELIABILITY; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; ASTROCYTOMA; BRAIN NEOPLASMS; CELL DIVISION; CHILD; CHILD, PRESCHOOL; CYCLIN-DEPENDENT KINASE INHIBITOR P16; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; KINETICS; MALE; MIDDLE AGED; OLIGODENDROGLIOMA; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TIME FACTORS;

EID: 0032947770     PISSN: 0167594X     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006185220369     Document Type: Article

References (31)

1. Weinberg R: The retinoblastoma protein and cell cycle control. Cell. 81: 323-330, 1995
2. Serrano M, Hannon GJ, Beach: A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 366: 704-707, 1993
3. Nobori T, Miura K, Wu DJ, Lois A, Takabayashi K, Carson DA: Deletions of the cyclin-depentent kinase-4 inhibitor gene in multiple human cancers. Nature 368: 753-756, 1994
4. Kamb A, Gruis NA, Weaver-Feldhaus J, Liu Q, Harshman K, Tavtigian SV, Stockert E, Day RS III, Johnson BE, Skolnick MH: A cell cycle regulator potentially involved in genesis of many tumor types. Science 264: 436-440, 1994
5. Olopade OI, Jenkins RB, Ransom DT, Malik K, Pomykala H, Nobori T, Cowan JM, Rowley JD, Diaz MO: Molecular analysis of deletions of the short arm of chromosome 9 in human gliomas. Cancer Res 52: 2523-2529, 1992
6. Nishikawa R, Furnari FB, Lin H, Arap W, Berger MS, Cavenee WK, Huang H-JS: Loss of p16INK4 expression is frequent in high grade gliomas. Cancer Res 55: 1941-1945, 1995
7. Ono Y, Tamiya T, Ichikawa T, Kunishio K, Matsumoto K, Furuta T, Ohmoto T, Ueki K, Louis DN: Malignant astrocytomas with homozygous CDKN2/p16 gene deletions have higher Ki-67 proliferation indices. JNEN 55: 1026-1031, 1996
8. Perry A, Nobori T, Ru N, Anderl K, Borell TJ, Mohapatra G, Feuerstein BG, Jenkins RB; Carson DA: Detection of p16 gene deletions in gliomas: a comparison of fluorescence in situ hybridization (FISH) versus quantitative PCR: J Neuropathol Exp Neurol 56: 999-1008, 1997
9. Sure U, Ruedi D, Tachibana O, Yonekawa Y, Ohgaki H, Kleihues P, Hegi ME: Determination of p53 mutations, EFGR overexpression, and loss of p 16 expression in pediatric glioblastomas. J Neuropathol Exp Neurol 56:788-789, 1997
10. Barker FG, Pengchin C, Furman F, Aldape KD, Edwarda MSB, Israel MA: P16 deletion and mutation analysis in human brain tumors. J Neuro-Oncol 31: 17-23, 1997
11. Piva R, Cavalla P, Bortolotto S, Cordera S, Grosso R, Richiardi P, Dutto A, Schiffer D: CDKN2/p16 inactivation p16 immunohistochemistry in astrocytic gliomas. Int J Oncol 12: 55-58, 1998
12. Arap W, Nishikawa R, Furnari FB, Cavenee WK, Su Huang HJ: Replacement of the p16/CDKN2 gene suppresses human glioma cell growth. Cancer Res 55: 1351-1354, 1995
13. Fueyo J, Gomez-Manzano C, Yung AWK, Clayman GL, Liu T-J, Bruner J, Levin VA, Kyritsis AP: Adenovirus- mediated p16/CDKN2 gene transfer induces growth arrest and modifies the transformed phenotype of glioma cells. Oncogene 12: 103-110, 1996
14. Li Y-J, Hoang-Xuang K, Delattre J-Y, Poisson M, Thomas G, Hamelin R: Frequent loss of heterozygosity on chromosome 9, and low incidence of mutations of cyclin-dependent kinase inhibitors p 15 (MTS2) and p16 (MTS1) genes in gliomas. Oncogene 11: 597-600, 1995
15. Moulton T, Samara G, Chung W-Y, Yan L, Desai R, Sisti M, Bruce J, Tycko B: MTS1/p16/CDKN2 lesions in primary glioblastoma multiforme. Am J Pathol 146: 613-619, 1995
16. Sonoda Y, Yoshimoto T, Sekiya T: Homozygous deletion of the MTS1/p16 and MTS2/p15 genes and amplification of the CDK4 gene in glioma. Oncogene 11: 2145-2149, 1995
17. Walker DG, Duan W, Popovic EA, Kaye AH, Tomlinson FH, Lavin M: Homozygous deletions of the multiple tumor suppressor gene 1 in the progression of human astrocytomas. Cancer Res 55: 20-23, 1995
18. Kyritsis AP, Zhang B, Zhang W, Xiao M, Takeshima H, Bondy ML, Cunningham JE, Levin VA, Bruner J: Mutations of the p16 gene in gliomas. Oncogene 12: 63-67, 1996
19. Merlo A, Herman JG, Mao L, Lee DJ, Gabrielson E, Burger PC, Baylin SB, Sidransky D: 5′CpG island methylation is associated with transcriptional silencing of the tumor suppressor p16/CDKN2/MTS1 in human cancers. Nature Med 1: 686-692, 1995
20. Kleihues P, Burger PC, Scheithauer BW: Histological typing of tumors of the central nervous system. WHO. Berlin, Springer-Verlag, 1993
21. Tam SW, Shay JW, Pagano M: Differential expression and cell cycle regulation of the cyclin-dependent kinase 4 inhibitor p16INK4. Cancer Res 54: 5816-5820, 1994
22. Xu L, Sgroi D, Sterner CJ, Beauchamp RL, Pinney DM, Keel S, Ueki K, Rutter JL, Buckler AJ, Louis DN, Gusella JF, Ramesh V: Mutational analysis of CDKN2 (MTS1/p16INK4) in human breast carcinomas. Cancer Res 54: 5262-5264, 1994
23. Geradts J, Kratzke RA, Niehans GA, Lincoln CE: Immunocytochemical detection of the cyclin-dependent kinase inhibitor 2/multiple tumor suppressor gene 1 (CDKN2/MTS1) product p16INK4A in archival human solid tumors: correlation with retinoblastoma protein expression. Cancer Res 55: 6006-6011, 1995
24. Sallinen P, Haapasalo HK, Visakorpi T, Helén P, Rantala IS, Isola JJ: Prognostication of astrocytoma patient survival by Ki-67 (MIB-1), PCNA, and S-phase fraction using archival paraffin-embedded samples. J Pathol 174: 275-282, 1994
25. Schmidt EE, Ichimura K, Reifenberger G, Collins VP: CDKN2 (p16/MTS1) gene deletion or CDK4 amplification occurs in the majority of glioblastomas. Cancer Res 54: 6321-6324, 1994
26. Costello JF, Berger MS, Huang Su H-J, Cavenee WK: Silencing of p16/CDKN2 expression in human gliomas by methylation and chromatin condensation. Cancer Res 56: 2405-2410, 1996
27. Fueyo J, Gomez-Manzano C, Bruner JM, Saito Y, Zhang W, Levin VA, Yung WKA, Kyritsis AP: Hypermethylation of the CpG island of p16/CDKN2 correlates with gene inactivation in gliomas. Oncogene 13: 1615-1619, 1996
28. Sato K, Schäuble B, Kleinhues P, Ohgaki H: Infrequent alterations of the p15, p16, CDK4 and cyclin D1 genes in non-astrocytic human brain tumors. Int J Cancer 66: 305-308, 1996
29. He J, Allen JR, Collins VP, Allalunis Turner MJ, Godbout R, Day RS III, James CD: CDK4 amplification is an alternative mechanism to p16 gene homozygous deletion in glioma cell lines. Cancer Res 54: 5804-5807, 1994
30. Ichimura K, Schmidt EE, Goike HM, Collins VP: Human glioblastomas with no alterations of the CDKN2/p16A (p16INK4A, MTS1) and CDK4 genes have frequent mutations of the retinoblastoma gene. Oncogene 13: 1065-1071, 1996
31. Talve L, Sauroja I, Collan Y, Punnonen K, Ekfors T: Loss of expression of the p16INK4/CDKN2 gene in cutaneus malignant melanoma correlates with tumor cell proliferation and invasive stage. Int J Cancer 74: 255-259, 1997